ARG1 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population established from the 786-O human renal cell adenocarcinoma line. This product comprises a heterogeneous mixture of edited cells carrying targeted disruptions in the ARG1 gene, generating a population-level loss of arginase 1 function. As polyclonal knockout cells, they avoid the biases of clonal selection and are not a monoclonal line; individual cells may vary in editing outcome, but the pooled phenotype reflects collective arginase deficiency.
The parental 786-O cell line is derived from a primary clear cell renal cell carcinoma (ccRCC). It displays epithelial morphology and carries a homozygous inactivating mutation in the von Hippel-Lindau (VHL) tumor suppressor gene, resulting in constitutive stabilization of hypoxia-inducible factors (HIFs). This well-characterized VHL-mutant background makes 786-O cells a canonical in vitro model for studying ccRCC biology, including metabolic reprogramming and oncogenic signaling.
ARG1 encodes arginase 1, a key enzyme of the urea cycle that catalyzes the hydrolysis of L-arginine into L-ornithine and urea. Beyond hepatic metabolism, ARG1 exerts a potent immunomodulatory function in the tumor microenvironment by depleting extracellular L-arginine, an amino acid critical for T-cell receptor (TCR) signaling. Arginine starvation leads to loss of CD3?? expression, impairing TCR complex formation and T-cell effector responses. ARG1 expression is upregulated by cytokines IL-4, IL-13, and TGFB1 through STAT6-mediated transcription. Downstream, L-ornithine fuels polyamine synthesis, further contributing to immunosuppression. ARG1 also competes with nitric oxide synthase (NOS) for L-arginine and functionally interacts with ornithine transcarbamylase (OTC) and argininosuccinate synthase (ASS1) within the broader arginine metabolic network.
In the context of 786-O ccRCC, knockout of ARG1 eliminates the capacity of tumor cells to deplete L-arginine, thereby restoring local arginine availability and potentially rescuing T-cell immune functions. The VHL-mutant status of these cells may intersect with arginine metabolism, as HIF-driven metabolic rewiring influences the urea cycle and polyamine pathways. Thus, this polyclonal knockout model provides a physiologically relevant platform to investigate the role of arginase-mediated immune evasion in renal cell carcinoma.
This product is designed for research applications in tumor immunology, cancer metabolism, and immunotherapy target validation. Standard characterization includes Western blotting or RT-qPCR to confirm ARG1 disruption, arginase activity assays, and L-arginine quantification. Functional co-culture assays with T cells enable measurement of T-cell proliferation, activation, and CD3?? expression by flow cytometry. Additional approaches such as urea cycle metabolite profiling and tumor xenograft growth assays extend the utility to in vivo tumor models. For further technical inquiries or custom solutions, please contact Ascent Research.
